09/04/2026
The FDA has approved Lisraya (brepocitinib) for adults with dermatomyositis, a rare inflammatory disease that can cause muscle weakness and distinctive skin changes. The approval gives adults living with this condition a new treatment option and adds another targeted therapy to the treatment landscape for rare autoimmune diseases. The FDA lists the approval date as August 27, 2026.